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MAGNETIC RESONANCE IMAGING RADIOMICS TO PREDICT HIGH-RISK 
INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS OF THE PANCREAS 
 
JULIANA BROOKE SCHILSKY 
ABSTRACT 
Background: Pancreatic cancer is one of the most lethal cancers. Despite enhanced 
understanding of the disease, the 5-year survival rate remains 8% due to the late stage of 
diagnosis and a lack of effective treatment options. Early detection of precancerous lesions, 
such as intraductal papillary mucinous neoplasms (IPMNs), is a strategy to prevent 
pancreas cancer related death. Standard qualitative imaging assessment cannot reliably 
distinguish between benign and malignant branch duct intraductal papillary mucinous 
neoplasms (BD-IPMNs). A more consistent risk prediction method is needed to inform 
clinical decision making such that patients with benign cysts may be spared from 
unnecessary surgical resection.  
Objective: To assess whether a BD-IPMN malignancy risk prediction model which 
demonstrated strong potential on preoperative computed tomography (CT) images would 
show similar results on magnetic resonance imaging (MRI). 
Methods: 19 pathologically proven BD-IPMN patients with preoperative contrast-
enhanced CT and MRI were included in the study. Five radiomics features were extracted 
from the portal-venous phase CT and MR images of the largest cyst. Associations between 
radiomics features extracted from CT and MR were assessed using Pearson correlations.  
 
 vi 
Results: Of the five radiomics features, average-weighted eccentricity (AWE) was most 
strongly correlated between imaging modalities in all patients (n=19, r=0.46, 95% 
CI=0.001-0.75, p=0.05), low-risk patients (r=0.63, 95% CI=0.09-0.88, p=0.028), and 
patients with a solid component or mural nodule (r=0.66, 95% CI=-0.32-0.96, p=0.15). 
However, when two outliers within the dataset were removed from analysis, AWE no 
longer correlated between MR and CT. None of the other radiomics features displayed 
significant correlations between the modalities.  
Conclusions: The CT-based risk prediction model cannot be applied to MR data 
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An estimated 55,440 new cases of pancreatic cancer were diagnosed in the United 
States in 2018, resulting in approximately 44,330 deaths (American Cancer Society 2018). 
Despite advances in care, pancreatic cancer remains the 4th leading cause of cancer-related 
death in the United States. It has become clear that the dismal 5-year survival rate of 8% is 
largely due to the typically late stage of diagnosis and lack of effective treatment options 
(American Cancer Society 2018). As such, early detection has become a focus of pancreatic 
cancer research efforts.  
Intraductal Papillary Mucinous Neoplasms (IPMNs) represent about 25% of all 
pancreatic cystic neoplasms and are the only radiographically identifiable precursor of 
pancreatic cancer (Sarr et al. 2003; Fasanella and McGrath 2009; Kosmahl et al. 2004). 
Early detection of pre-cancerous lesions helps inform treatment decisions and is currently 
the best method for pancreatic cancer prevention (Del Chiaro et al. 2014). Although up to 
40% of resected IPMNs are already associated with invasive carcinoma (Matthaei et al.  
2011; D'Angelica et al. 2004), many patients with benign IPMN are not accurately 
identified at presurgical screening and proceed to unnecessary resection. Due to the high 
morbidity of pancreatic resection (Beger, Mayer, and Poch 2018; D'Angelica et al. 2004), 
current efforts are aimed at improving risk assessment of IPMNs with the goal of more 





Clinical Features of Intraductal Papillary Mucinous Neoplasms 
IPMNs are slightly more common in men and are usually found in patients over 60 
years old (Sarr et al. 2003; Fasanella and McGrath 2009; Reid-Lombardo et al. 2008). 
Patients with low-risk IPMN are often asymptomatic but may present with abdominal pain 
and acute or chronic pancreatitis. The presence of clinical symptoms tends to correlate with 
increased dysplasia and malignancy. The clinical presentation of patients with invasive 
IPMN may include weight loss, jaundice, new onset or worsening diabetes, gastrointestinal 
dysfunction, and other symptomatology typical of pancreatic adenocarcinoma patients 
(D'Angelica et al. 2004; Sakorafas et al. 2011).  
IPMNs are not detectable on routine lab screening. Blood and urine tests, including 
liver function, amylase and lipase are typically normal or show non-specific changes 
(Sakorafas et al. 2011). While not reliable, tumor markers such as cancer antigen (CA) 19-
9, carcinoembryonic antigen and CA 125 may help differentiate benign from malignant 
IPMNs (Xu et al. 2011; Sakorafas et al. 2011).  
 
IPMN Pathology  
IPMNs are mucin-producing cysts that arise from pancreatic ductal epithelium and 
form papillary projections into the ductal system (Campbell et al. 2015; Sakorafas et al.  
2011). IPMNs can thus be located anywhere throughout the pancreatic ductal system, from 
the head to the tail, and within main or branch ducts, but are most commonly seen in the 
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pancreatic head (Sarr et al. 2003). IPMNs are classified by location within the ductal 
system, histologic grade of dysplasia, and histomorphologic pattern of papillae. 
Since IPMN arising in the main pancreatic duct have greater potential of malignancy, 
IPMN are clinically classified by location into: main duct (MD)-IPMN, branch duct (BD)-
IPMN, and mixed type (Kobari et al. 1999). MD-IPMN present with prominent intraductal, 
papillary projections and are associated with diffuse or segmental main duct dilation 
(Figure 1a; Sarr et al. 2003). BD-IPMN arise in a side branch of the main pancreatic ductal 
system, typically in the pancreatic head or uncinate process. Depending on location, BD-
IPMN may also cause main duct dilation (Figure 1b). These BD cysts are often smaller 
and asymptomatic, resulting in greater diagnostic uncertainty (Sakorafas et al. 2011). 
Mixed type IPMN involves both main pancreatic duct and side branches and are typically 
considered of similar malignant potential to MD-IPMN (Sahora et al. 2014).  
 
 
Figure 1: Gross pathology of IPMN. Left, high risk cystic lesion with papillary structure 
located within the main pancreatic duct. Right, low risk cystic lesion without nodular or 
papillary structures; dilated main pancreatic duct. Photographs courtesy of Askan Gokce, 




The WHO classifies IPMN based on degree of cellular atypia and invasiveness 
(Longnecker et al. 2000). IPMN without dysplasia are benign adenomas. Borderline IPMN 
have low- to intermediate-grade dysplasia, and IPMN with high-grade dysplasia are 
carcinoma in situ. IPMN with an invasive component are considered invasive carcinoma 
(Hruban et al. 2004; Tanaka et al. 2006). More recently, intermediate-grade dysplasia has 
been eliminated as a category and these IPMN are now categorized as low-grade tumors.  
Histomorphologic patterns observed in IPMN include gastric, intestinal, 
pancreatobiliary, and oncocytic (Furukawa et al. 2005; Adsay et al. 2004). Gastric type 
lesions, previously reported as clear-cell or null type IPMN, are mostly found in branch 
ducts and resemble gastric foveolae (Figure 2b). They are the only morphological IPMN 
subtype that may have abundant flat areas in addition to thick finger-like papillae and are 
often diagnosed as adenomas due to their low-grade atypia (Ban et al. 2006; Furukawa et 
al. 2005). Intestinal type morphology is usually found in MD-IPMN. These lesions 
phenotypically resemble intestinal villous adenomas and often contain a moderate to severe 
degree of atypia, with about 85% harboring carcinoma in situ (Adsay et al. 2004; Ban et 
al. 2006; Furukawa et al. 2005). Pancreatobiliary type lesions mimic neoplastic 
cholangiopapillary morphology and are seen in about 20% of IPMN (Figure 2a). This type 
of lesion harbors severe atypia, with 94% associated with carcinoma in situ, and is 
commonly associated with a more aggressive clinical course characterized by tubular type 
invasive carcinoma (Adsay et al. 2004; Furukawa et al. 2005). Oncocytic lesions are less 
common neoplasms characterized by high atypia, complex branching papillae and 
abundant eosinophilic cytoplasm (Furukawa et al. 2005). 
 
5 
    
Figure 2: Microscopic pathology of IPMN. Left, high risk pancreatobiliary type IPMN. 
The interconnecting papillae are lined by cuboidal epithelium which is more complex, 
atypical and pleomorphic. Right, low risk gastric type IPMN. Gastric foveolar type 
epithelium line the papillae. Photographs courtesy of Askan Gokce, David M. Rubenstein 
Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center. 
 
Radiologic Imaging Features of IPMN 
Pancreatic cysts are often first evident after noninvasive imaging, which is 
sometimes performed after patients begins experiencing clinical symptoms associated with 
pancreatic disease (Sarr et al. 2003). However, due to the lack of early distinct clinical 
symptoms associated with IPMN, these lesions are not uncommonly reported as incidental 
imaging findings (Lana et al. 2016). Radiologic imaging is essential in preoperative 
diagnosis of IPMN, sub-classification of disease, and assessment of malignancy risk.  
IPMN may be imaged through a variety of modalities. Noninvasive imaging 
techniques include ultrasonography, computed tomography (CT), and magnetic resonance 
imaging (MRI), including magnetic resonance cholangiopancreatography (MRCP). 
Minimally invasive imaging techniques include endoscopic ultrasonography, and 
endoscopic retrograde cholangiopancreatography (ERCP) (Sarr et al. 2003; Fukukura et al.  
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2000; Taouli et al. 2000). The most commonly used techniques in noninvasive pancreatic 
imaging are CT and MRI.  
Guidelines by the American College of Radiology Incidental Findings Committee 
released in 2010 and a 2012 consensus statement by the International Association of 
Pancreatography indicate a preference for MRI over CT imaging for characterizing 
pancreatic lesions (Berland et al. 2010; Tanaka et al. 2012). However, the literature 
suggests little difference in accuracy between MRI and CT for qualitatively characterizing 
cystic pancreatic lesions (Visser et al. 2007). Thus, CT with intravenous (IV) contrast is 
typically the initial comprehensive imaging choice for patients with suspected pancreatic 
cancer, due to its ability to yield thin slice cuts, high image resolution, fast image 
acquisition and a diagnostic sensitivity of 76-92% (Ahn et al. 2009; Amin et al. 2006; 
Ichikawa et al. 1997; Palazzo et al. 1993; Sheridan et al. 1999).  
The use of IV contrast in CT imaging is important for accurate diagnosis of 
pancreatic lesions. Modern CT contrast scan protocols use three acquisition phases. The 
first acquisition is taken pre-contrast and is useful for basic pancreatic localization and 
identification of pancreatic calcifications. The second phase, late arterial or pancreatic 
parenchymal phase, is acquired 30-40 seconds after contrast injection. During this phase, 
differences in contrast enhancement between pancreatic neoplasms and normal 
parenchyma is maximized. The portal venous phase is the third acquisition, taken 70-90 
seconds after contrast injection, and can offer the best contrast for identifying primary 
pancreatic lesions (Katz 2012). Contrast enhanced imaging is relatively contraindicated in 
patients with renal failure or contrast allergy; the clinical application of non-contrast CT 
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imaging of pancreatic IPMNs and adenocarcinomas is limited (Tummala, Junaidi, and 
Agarwal 2011). 
Pancreatic ductal adenocarcinomas (PDAC) are often poorly circumscribed 
hypovascular masses, and therefore appear hypoattenuating to the surrounding parenchyma 
in early phase dynamic CT, but gradually enhance with delayed imaging and can appear 
isoattenuating in later phases (Tummala, Junaidi, and Agarwal 2011). Early stage PDAC 
may be difficult to detect on CT imaging as smaller tumors can appear isoattenuating to 
the pancreatic parenchyma on all post-contrast phases. Advanced stage PDAC is more 
readily detected on CT imaging, and is commonly associated with involvement of major 
local arteries and veins, peripancreatic adenopathy, ascites, or hepatic metastases (Katz 
2012).   
On the other hand, IPMN are predominantly cystic and appear non-enhancing on 
CT. IPMN that develop enhancing mural nodules are considered suspicious and have a 
higher likelihood of harboring malignancy. The characteristic imaging signature of MD-
IPMN is diffuse or segmental dilation of the main pancreatic duct. Main duct dilation is 
less common for BD-IPMN. However, BD-IPMN most often present in the pancreatic head 
and can cause compression of the common bile duct with resultant dilation of intrahepatic 
bile ducts which may be visible on CT imaging. BD-IPMN may appear as a single lesion 
or as a fluid attenuation cluster of round or tubular lesions (Katz 2012).  
MRI is also used to screen and characterize pancreatic lesions, and to stage 
pancreatic cancers. In fact, cystic lesions are recognized with greater frequency on MRI 
 
8 
(19.9%) compared to CT (1.2-2.6%) when encountered incidentally (Zhang et al. 2002; 
Spinelli et al. 2004; Laffan et al. 2008). 
MRI of the pancreas is performed using IV contrast containing gadolinium. The 
scan protocols for MRI use acquisition phases which are analogous to those for CT 
imaging. MRI is relatively contraindicated in patients with gadolinium contrast allergy and 
certain implants (Tummala, Junaidi, and Agarwal 2011).  
MRI may be better than CT for characterizing cystic lesions of the pancreas due to 
its high soft tissue contrast (Tummala, Junaidi, and Agarwal 2011; Grutzmann et al. 2011; 
Larozza 2016). The improved soft tissue contrast of MRI imaging may be particularly 
helpful in depicting risk associated stigmata such as septations, thick enhancing walls, 
mural nodules, and soft tissue components (Gerst and Do 2012). During the portal venous 
phase on gadolinium-enhanced T1-weighted imaging, the cystic fluid component of IPMN 
appears hypointense while solid components and mural nodules that enhance appear 
hyperintense. The opposite is observed on T2-weighted imaging, with the cyst appearing 
bright and the nodules appearing darker (Tummala, Junaidi, and Agarwal 2011). MRI may 
also be particularly useful for accurate assessment of metastasis-associated features of 
PDAC such as vascular invasion or encasement, and locoregional tumor extension (Gerst 
and Do 2012).     
IPMN Features Associated with Risk 
The Sendai criteria, and more recently, the Fukuoka consensus guidelines, have 
helped to establish radiological criteria to guide IPMN assessment and care. Guidelines for 
BD-IPMN and MD-IPMN differ greatly. Given the high frequency of invasive carcinoma 
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and high-grade dysplasia in MD-IPMN, almost all patients with MD-IPMN undergo 
resection (Tanaka et al. 2017). Mixed-type IPMN are treated similarly to MD-IPMN; they 
are also considered at high risk for malignancy and are generally recommended for surgical 
resection (Sakorafas et al. 2011).  
Management of BD-IPMN is more controversial as only approximately 18% of 
resected tumors are malignant (Campbell et al. 2015). The variable risk in BD-IPMN is 
evaluated based on several key characteristics. 
The presence of clinical symptoms is strongly indicative of invasive IPMN (Tanaka 
et al. 2006; Sakorafas et al. 2011; Sugiyama et al. 2003). Indeed, Fasanella and McGrath 
(2009) recommend resection of all symptomatic IPMN, even in the absence of high-risk 
imaging features (Fasanella and McGrath 2009). 
Imaging features most strongly associated with risk of malignancy, termed high-
risk stigmata, include presence of an enhancing mural nodule or solid component (Figure 
3), especially if greater than 5 mm, and main pancreatic duct dilation greater than 10 mm 
(Tanaka et al. 2006; Sakorafas et al. 2011; Sugiyama et al. 2003; Fasanella and McGrath 
2009). Increased diameter of these features correlates with increased risk of malignancy. 
Surgical resection should be strongly considered for these patients, where clinically 
appropriate.  
Worrisome features include main pancreatic duct dilation of 5-9 mm, abrupt change 
in main duct caliber, cyst diameter of 3 cm or greater, enhancing mural nodule less than 5 
mm, thickened enhancing cyst walls, cyst growth rate of more than 5 mm in two years, 
lymphadenopathy and extrapancreatic malignancy (Sugiyama et al. 2003; Tanaka et al.  
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2006; Jang et al. 2008; Tanaka et al. 2012; Tanaka et al. 2017). Endoscopic US is 
recommended for patients presenting with any of these worrisome characteristics. Surgical 
intervention should be considered if any of the following features are observed at 
endoscopic US: definite mural nodule of 5 mm or greater, or features suspicious of main 
duct involvement, such as intraductal mucin (Tanaka et al. 2017).   
According to the Fukuoka guidelines, BD-IPMN without any of the high-risk 
stigmata or worrisome features noted above (Figure 4) are recommended for a more 
conservative approach of watchful waiting, especially in patients who are considered poor 
candidates for surgery (Tanaka et al. 2012; Tanaka et al. 2017; Vege et al. 2015). 
Guidelines for surveillance in these patients are based on cyst size. Patients with IPMN 
measuring less than 1 cm are recommended for imaging follow up at 6 months, and then 
every two years if no change is observed. Patients with IPMN measuring between 1-3 cm 
are recommended for more frequent follow up imaging (Tanaka et al. 2017). During follow 
up it is important to monitor for clinical symptoms, increase in tumor size and worrisome 
radiographic characteristics, any of which might indicate reconsideration of surgical 
intervention (Sakorafas et al. 2011).  
Accurate assessment of high risk BD-IPMN features on imaging, either CT or MRI, 
is thus crucial for clinical management. While measurements of dominant cyst and main 
pancreatic duct show high interobserver agreement, detection of the presence of a mural 
nodule or solid component is less consistent among radiologists (Do et al. 2014). Thus, a 
more objective, quantitative method of BD-IPMN risk assessment would potentially 
improve prognostication and clinical decision making. 
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Radiomics in Oncologic Imaging   
Radiomics is the process of high-throughput extraction of large numbers of 
quantitative features from radiologic images. These data provide a more objective high-
dimensional supplement to traditional visual interpretation of biomedical images and are 
used for hypothesis generation, testing and clinical decision support. Correlating and 
combining radiomics data with clinical information can increase the power of evidence-
based decision support models, thereby enhancing prognostication and prediction of 
disease (Gillies, Kinahan, and Hricak 2016).  
Over the past decade, radiomics has become an increasingly popular area of 
investigation in oncologic imaging. Radiomics analysis in research has led to the 
identification of numerous imaging biomarkers which aid in cancer detection and enhance 
clinical prediction models for a variety of oncologic diseases. Quantitative imaging 
features based on intensity, shape, volume and texture provide unique information on 
tumor phenotype and surrounding environment, and can aid in the characterization of 





Figure 3: MR and CT imaging examples of high-risk IPMN. Top, portal venous phase 
CT angiogram with a prominent IPMN in the uncinate process. Bottom, the same IPMN 
visualized on portal venous phase T1-weighted MRI. Red arrows depict mucinous cystic 




Figure 4: MR and CT imaging examples of low-risk IPMN. Top, portal venous phase 
CT angiogram with a simple, homogenous IPMN in the body of the pancreas. Bottom, the 
same IPMN visualized on portal venous phase T1-weighted MRI. Red arrows depict 





Texture analysis has led the way in the field of radiomics thus far. Texture analysis 
employs a variety of quantitative methods to evaluate statistical relationships between 
pixels or voxels with similar or dissimilar contrast values, using measures such as the gray-
level intensity and position of pixels within an image to derive texture features. These 
texture features can provide measures of intratumoral heterogeneity, an indicator of poor 
prognosis, beyond what is readily appreciated by visual assessment. (Davnall et al. 2012; 
O'Connor et al. 2015). Although pathologic assessment is the current gold standard for 
diagnosis of disease, biopsies contain only a limited portion of tumor tissue and thus texture 
analysis may better represent the full extent of intratumoral variation (Davnall et al. 2012). 
Texture analysis can also distinguish areas of different cellular density in tumors (Lloyd et 
al. 2010), which might suggest a role for texture analysis in the detection of mural nodule 
or solid tumor components in IPMN.  
Each imaging modality presents different challenges to texture analysis. While 
much of the heterogeneity visible on CT may be due to photon noise rather than underlying 
biology, CT is currently the leading imaging modality for texture analysis, likely due to its 
superior resolution (Davnall et al. 2012; Alobaidli et al. 2014). MRI texture analysis has 
been less broadly studied, likely because scanner and sequence acquisition parameters have 
a less direct influence on signal intensity and quantification of heterogeneity compared 
with CT. Additionally, MRI imaging may be more susceptible to imaging artifacts than CT 
due to patient movement during long MR acquisitions, which affects pixel patterns 
captured by radiomic-based analysis (Davnall et al. 2012). Nevertheless, MRI may emerge 
as an important modality in texture analysis due to its superior soft tissue contrast which 
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may better highlight underlying biological heterogeneity in tumors (Alobaidli et al. 2014; 
Larozza 2016).  
Radiomics studies by organ system or specific tumor type are largely limited to one 
predominant imaging modality. This likely reflects the more common choice of imaging 
modality that is used for cancer screening in these organs. However, since radiomics 
analysis has the potential to yield information beyond what is appreciated on qualitative 
imaging analysis, it may be prudent to investigate the use of radiomics analysis on a variety 
of imaging modalities in each organ system.  
A number of prior studies, such as those listed in Table 1, have investigated the use 
of CT and MRI radiomics separately. However, no studies to date have compared the use 























Brain MRI 32 Histogram-based  Radiomics analysis may be useful in 
discriminating between indolent and quickly 
progressing forms of glioblastoma (Zhou et al. 
2014). 
Brain MRI 22 Novel/a priori 
defined radiomics 
imaging features 
A radiogenomics model may be useful for 
assessing intratumoral distribution of gene-
expression patterns in glioblastoma, aiding in 
the identification of more malignant 
phenotypes (Diehn et al. 2008). 
Colon/ 
Rectum 
CT 57 Histogram-based 
texture  
Texture measures representing low 
heterogeneity in colorectal tumors may predict 
poorer five-year survival (Ng et al. 2013). 
Colon/ 
Rectum 
CT 366 First-order statistics, 
size and shape-
based, texture and 
wavelet features 
A radiomics signature may be useful for 
histologic grade discrimination in colorectal 
adenocarcinomas (Huang et al. 2018). 
Colon/ 
Rectum 
CT 494 Histogram-based 
texture 
A histogram-based radiomics signature may 
be useful for discriminating between early and 
late stage colorectal tumors (Liang et al. 
2016). 




based texture  
A texture-based radiomics prediction model 
may be helpful for distinguishing between 
pathologically distinct renal neoplasms 
(Raman et al. 2014). 
Kidney CT 100 Gray-level texture 
features 
Texture features may be superior to qualitative 
assessment for distinguishing between fat-
poor angiomyolipoma and renal cell 
carcinoma (Hodgdon et al. 2015). 
Liver CT 235 Histogram-based 
texture 
Texture analysis of hepatic lesions may be 
useful for predicting therapeutic response to 
cytotoxic chemotherapy in patients with 
primary colorectal cancer and hepatic 
metastasis (Ahn et al. 2016). 
Lung CT 108 Convexity, entropy 
ratio 
Convexity and entropy ratio may aid in 
prognostication of patients with early stage 
lung adenocarcinoma (Grove et al. 2015). 
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Lung CT 14 Histogram-based 
texture 
Histogram-based texture quantifiers are 
potential imaging biomarkers of intratumoral 
heterogeneity (Ganeshan et al. 2013). 
Lung CT 66 Gray-level texture 
features 
Some gray-level texture features may be 
useful for distinguishing epidermal growth 
factor receptor mutation status in lung 
adenocarcinomas (Ozkan et al. 2015). 
Prostate MRI 143 Haralick texture Entropy, inertia, energy, correlation and 
homogeneity may be useful for prostate 
cancer detection and Gleason score 
computation (Wibmer et al. 2015). 
Prostate MRI 381 First-order statistics, 
histogram-based 
texture, Haralick 
texture, form factor 
parameters 
A radiomics-based model may be superior to 
standard reporting criteria for distinguishing 
between benign and cancerous prostate tumors 
(Chen et al. 2019). 
 
  
Radiomics in Pancreatic Oncology   
Radiomics studies of pancreatic cancer, and especially of IPMN, are limited, but 
have shown promise in recent years. In 2016, two preliminary studies exhibited the 
potential for texture analysis to predict histopathological grade and malignancy in IPMN 
(Hanania et al. 2016; Permuth et al. 2016). Hanania et al. (2016) investigated whether CT-
derived texture features related to intensity, texture and shape could be used to differentiate 
between high-grade and low-grade IPMN in 53 surgically-resected patients with 
pathologically confirmed IPMN. Using cross-validation and logistic regression, they 
demonstrated that gray-level co-occurrence matrix imaging biomarkers predicted IPMN 
histopathological grade with a sensitivity of 97% and specificity of 88% (Hanania et al.  
2016). Permuth et al. (2016) took a unique approach in their investigation by combining 
CT-derived texture features with micro-RNA genomic data to predict IPMN malignancy 
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in 38 surgically-resected patients with pathologically confirmed IPMN. Although radiomic 
features alone did not differentiate malignant from benign IPMN better than standard 
Fukuoka criteria, the radiogenomics (association between imaging features and genomic 
data) approach which combined these features with micro-RNA data was able to 
distinguish IPMN malignancy with a greater sensitivity and specificity than either the 
Fukuoka criteria or micro-RNA data alone (Permuth et al. 2016). Although these studies 
have limited generalizability and clinical application due to small sample size, inclusion of 
both MD and BD-IPMN in analyses, and substantial data overfitting, they successfully 
exhibited proof-of-concept for future applications of quantitative imaging analysis in 
IPMN.  
In the same year, Hyun et al. (2016) investigated the use of 18F-fluorodeoxygluc ose 
(FDG) PET texture analysis in assessing prognosis of patients with pancreatic ductal 
adenocarcinoma (PDAC). They extracted histogram-based and higher-order texture 
features from pretreatment 18F-FDG-PET/CT, along with standard PET parameters 
including metabolic tumor volume, total lesion glycolysis and standard uptake volume. The 
investigators found that first-order entropy was the single best predictor of overall survival, 
and that while higher entropy was independently associated with poorer survival outcomes 
on multivariate analysis, none of the standard PET parameters could independently predict 
survival (Hyun et al. 2016). Thus, it is apparent that, as has been demonstrated for several 
other types of cancer, heterogeneity provides a measure of malignancy in PDAC, and 
textural analysis of heterogeneity will be important for accurate prognostication in a variety 
of diseases.  
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In 2017, Chakraborty et. al investigated whether tumor heterogeneity quantified by 
CT texture analysis could be used to predict 2-year survival in 35 PDAC patients who 
underwent neoadjuvant chemotherapy with gemcitabine and oxaliplatin prior to resection. 
They found that texture features, particularly angle co-occurrence matrices, could be used 
to predict survival with an accuracy of 83%. Importantly, differences in angle co-
occurrence matrices may reflect areas of necrosis within the tumor which would have 
developed prior to neoadjuvant therapy, suggesting the application of texture analysis to 
distinguish underlying biological differences and inform clinical decision making 
(Chakraborty et al. 2017).  
In a 2018 study by Attiyeh et al., CT texture analysis was combined with 
preoperative serum CA19-9 levels and composite pathology scores to construct a novel 
survival prediction model. A total of 161 chemotherapy-naïve, surgically-resected patients 
were included in the analysis. The model was constructed using data from 70% of the 
patients as a training set, and the remaining 30% were used for independent validation. On 
validation, the model achieved a concordance index of 0.74 and an integrated Brier score 
of 0.200 (Attiyeh, Chakraborty, Doussot, et al. 2018). The investigators thus identified a 
way to harness important post-resection pathological information to preoperatively and 
non-invasively predict survival in patients with PDAC.  
Some researchers have recently investigated radiomics changes associated with 
treatment response in pancreatic cancers. Ciaravino et al. (2018) evaluated the use of CT 
texture analysis in restaging PDAC after neoadjuvant therapy. A total of 31 PDAC patients 
were included in the analysis, 17 of whom were initially un-resectable but able to proceed 
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to resection after chemotherapy, and 14 of whom had disease progression. They found a 
significant decrease in kurtosis on follow-up CT scans of patients who were downstaged 
after neoadjuvant treatment, but no change in kurtosis was seen on follow-up CT for 
patients with disease progression (Ciaravino et al. 2018). In keeping with the movement 
toward precision medicine in oncology, future research should also focus on the 
identification of early imaging biomarkers in pancreatic tumors which could predict 
response to specific therapies. This would be particularly pertinent for deciding whether 
patients with unresectable pancreatic tumors would benefit from neoadjuvant treatment and 
would spare those unlikely to respond from unnecessary toxicity associated with 
chemotherapy.  
In 2017, Hoffman et al. were the first to use MRI-extracted radiomics for the 
characterization of BD-IPMN. They investigated the prognostic value of 3D whole-lesion 
histogram-based radiomics features extracted from MRI in 18 surgically-resected patients 
with pathologically confirmed BD-IPMN. While mean apparent diffusion coefficient, 
skewness and kurtosis were not useful for assessing malignancy in IPMN, the investigators 
showed that entropy could distinguish between benign and malignant IPMN with a 
sensitivity of 100%, specificity of 70% and an accuracy of 83% (Hoffman et al. 2017).  
In previous studies completed at Memorial Sloan Kettering Cancer Center 
(MSKCC), Chakraborty et al. (2018) and Attiyeh et al. (2018) retrospectively identified 
103 patients with pathologically proven BD-IPMN and baseline contrast-enhanced CT who 
underwent pancreatic resection between 2005 and 2015 (Chakraborty et al. 2018; Attiyeh, 
Chakraborty, Gazit, et al. 2018). Attiyeh et. al (2018) used CT texture analysis and a novel 
 
21 
quantitative mural nodularity feature in their risk prediction model. They demonstrated an 
increase in risk prediction of almost 20% when quantitative imaging features were added 
to the clinical variable prediction model (Attiyeh, Chakraborty, Gazit, et al. 2018). 
Chakraborty et. al (2018) assessed a novel risk prediction model using unique 
radiographically inspired features along with standard texture features extracted from CT. 
The radiographically inspired features demonstrated robust risk predictive power in BD-
IPMN (AUC=0.77) and was comparable to a model which included clinical variables 
(AUC=0.81) (Chakraborty et al. 2018).  
Radiomics studies of IPMN malignancy risk have been largely limited to analysis 
of features extracted from CT images. However, MRI can superiorly characterize subtle 
differences in contrast, IPMN are more commonly reported as incidental findings on MRI, 
and MRI is more frequently used for IPMN follow-up. Thus, MRI-extracted texture 
features may provide a more sensitive and robust assessment of less consistently detected 
risk-associated features such as mural nodules and solid enhancing components.  
In the above-mentioned studies completed at MSKCC, the investigators 
demonstrated that radiographically inspired features and a mural nodularity feature 
extracted from the CT images could predict the risk of BD-IPMN with considerably greater 
accuracy than standard radiologic assessment (Chakraborty et al. 2018; Attiyeh, 
Chakraborty, Gazit, et al. 2018). The present study investigates whether this CT-based BD-







Study design and patients  
A waiver of Health Insurance Portability and Accountability Act and informed 
consent was obtained through the Institutional Review Board at our institution to conduct 
this study. An overview of the study design is outlined in Figure 5. 
Patients were included if they were previously one of the 103 patients included in 
Chakraborty et al. and Attiyeh et al.’s 2018 studies, and they had a contrast-enhanced 
baseline MRI within 2 months of their pre-surgical CT. 26 patients initially met these 
inclusion criteria. 7 patients were then excluded due to poor scan quality as reviewed by a 
radiologist, resulting in 19 patients in the present study.  
Grade of dysplasia found at resection was assessed by an expert pathologist as part 
of routine clinical care and categorized into low-risk and high-risk based on standard 







Figure 5: Overview of methods. The patient undergoes MR and CT imaging within a 
period of two months. The cyst and pancreas are manually outlined on every axial slice. 




Patients underwent contrast-enhanced MRI imaging as part of routine clinical 
management. As in the prior CT radiomics studies (Chakraborty et al. 2018; Attiyeh, 
Chakraborty, Gazit, et al. 2018), the comparable post contrast imaging series was analyzed, 
i.e. the portal venous phase of contrast enhancement. The majority of patients were 
examined at a magnetic field strength of 1.5 T (n=15), and four patients were scanned at 
3.0 T. The following acquisition parameters were used for the T1 weighted sequences: 
median repetition time (TR) = 4.24 msec (range = 3.30-250 msec), average echo time (TE) 
= 1.95 msec (range = 1.17-4.20 msec), average slice spacing = 3.3 mm (range = 2.2-8.0 
mm), average pixel spacing = 1.03 x 1.03 mm (range = 0.59 x 0.59 mm – 1.64 x 1.64 mm), 
and average pixel resolution = 1.3 x 2.2 mm (range = 1.0 x 1.7 – 1.6 x 2.7 mm). 
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The contrast-enhanced CT images included in this study had a pixel resolution of 
0.8243 x 0.8243 mm. Additional acquisition parameters for these CT images are described 




 After acquiring the images, the cyst and pancreas regions were manually segmented 
by an experienced radiologist, blinded to outcome, using surgical planning software 
(ScoutTM Liver, Analogic Corporation, Peabody, MA). When more than one IPMN was 
present, the largest cyst was chosen for segmentation. 
 
Extraction of novel radiomics features  
The MRI images were quantitatively assessed by extracting five features which 
Chakraborty et al. (2018) and Attiyeh et al. (2018) based on radiographic observations 
related to high-risk disease (Chakraborty et al. 2018; Attiyeh, Chakraborty, Gazit, et al.  
2018).  
Adaptive thresholding was applied to capture high-intensity pixels, representing the 
solid component, and low-intensity pixels, representing the cystic fluid component. The 
cyst and pancreas regions were initially smoothed to remove small fluctuations using an 
average filter of size of 3 x 3 pixels. The filtered image was then thresholded to find the 
low and high-intensity pixels of the cyst and pancreas. The threshold was computed by 
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sorting all the pixels within the cyst and pancreas regions in ascending order of intensity, 
and the threshold was selected such that 90% of the total pixels were less than that intensity. 
The intensity threshold is computed as:  
IT𝑐𝑐 = I𝑐𝑐  ≥  𝑇𝑇ℎ𝑐𝑐 
IT𝑝𝑝 = I𝑝𝑝  ≤  𝑇𝑇ℎ𝑝𝑝 
 
Thi = Isi (n), where n = (0.9)(Ni), and i ∈ [c, p], where c represents cyst and p represents 
pancreas. Isi contains ascending sorted intensity of the segmented region, Ii, and Ni is the 
total number of pixels in the segmented region. ITi is the thresholded image, such that ITc 
is the thresholded cyst region and ITp is the thresholded pancreas region. For the cyst 
region, pixels greater than the threshold, i.e. pixels constituting the top 10% of intensity in 
the cyst region, are termed “enhanced pixels” for the cyst region. These high-intensity 
pixels represent the solid component of the cyst. For the pancreas region, pixels less than 
the threshold, i.e. pixels constituting the bottom 10% of intensity of the pancreas represent 
the fluid component of the cyst.   
 Boundary and non-boundary regions of the cyst were defined based on radiologist’s 
observations and thus the segmented region of interest. The boundary width was selected 
as three pixels. Let Nc,b and Nc,in be the number of boundary pixels and non-boundary pixels 
of the segmented cyst region. Boundary and non-boundary regions are mutually exclusive.  
 The features were extracted from all image slices and each feature was averaged 
across the slices to obtain the final feature value for the image. The following novel 
radiomics features were thus extracted from the cyst region: enhanced boundary fraction 
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(EBF), enhanced inside fraction (EIF), filled largest connected component fraction 
(FLCCF), average-weighted eccentricity (AWE), and mural nodularity feature (MNF). 
 
Enhanced boundary fraction (EBF)  
 EBFc is defined as the ratio of enhanced boundary pixels of the cyst to the total 






This feature quantifies enhancement of the cyst wall.  
  
Enhanced inside fraction (EIF)  
 EIFc is the fraction of enhanced non-boundary pixels of the thresholded cyst to the 





This feature quantifies the high-intensity pixels within the cyst caused by solid-enhancing 
component. 
 
Filled largest connected component fraction (FLCCF) 
 The filled largest connected component (FLCC) is the largest enhanced area 
obtained by filling the largest enhanced component within the non-boundary region. ITi 
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contains K number of connected components: cc1, cc2 …, ccK; after filling the holes inside. 
Then ccmax is the largest region representing FLCC.  
FLCCFc is the ratio of the area of the filled largest connected components of the 





This feature quantifies the area of the largest enhancing component within the cyst caused 
by the single largest solid-enhancing component.  
 
Average-weighted eccentricity (AWE)  
 Sometimes several connected components are found with size close to the largest 
connected component (FLCC), such that consideration of only the largest component may 
miss some information. The average-weighted eccentricity of the cyst (AWEc) is based on 
the combined area of enhancing connected cystic components within close proximity to 
each other, and is defined as:  
AWE𝑐𝑐 =  
∑ (𝑐𝑐𝑐𝑐𝑘𝑘)∗ 𝐸𝐸𝑐𝑐𝑐𝑐(𝑐𝑐𝑐𝑐𝑘𝑘)𝐾𝐾𝑘𝑘=1  
∑ Area (𝑐𝑐𝑐𝑐𝑘𝑘)𝐾𝐾𝑘𝑘=1
 
Ecc(cck) represents the eccentricity of cck, the connected components. This feature 
quantifies the area of larger enhancing components within the cyst caused by a number of 




Mural nodularity feature (MNF) 
 Inspired by the appearance of IPMN mural nodules, this feature measures the ratio 
of the area of the largest connected enhanced region and the area of the cyst region, 





The area of the largest connected enhanced region, ccmax,c, and the area of the cyst, Nc 
include both the boundary and non-boundary region. 
 
Analysis 
 The proposed method of feature extraction and computation was implemented in 
MATLAB, version R2015a (Natick, MA, USA).  
The association between radiomics features extracted from MR and CT was 
assessed using r-value computed with Pearson correlation. The risk prediction value of 
MRI and CT was assessed separately on each of the radiomics features by computing 








 Of the 19 patients included in the present study, 7 (36.8%) were high-risk and 12 
(63.2%) were low-risk. The median age was 66 years (range = 44-82). Gender was split 
evenly [male: 9 (47.4%); female: 10 (52.6%)]. The median number of weeks between 
preoperative MRI and operation was 8.0 weeks (range = 2.9-30.3). The median number of 
weeks between preoperative MRI and CT was 2.14 weeks (range = 0.28-8.86). A mural 
nodule was reported preoperatively in 4 (21.1%) patients, and a solid component was 
reported in 2 (10.5%) patients. 2 (16.7%) low-risk patients had reports of a mural nodule, 
solid component, or both, while this was reported in 4 (57.1%) of high-risk patients. 
Detailed patient characteristics are available in Table 2.  
 
Comparison of MR and CT extracted radiomics features in all patients 
 Pearson correlations were calculated for each of the radiomics features extracted 
from MR and CT. When all patients were included in the correlation (n = 19), AWE 
demonstrated a moderate correlation approaching significance between CT and MR (r = 
0.4552, 95% CI = 0.001236 – 0.7536, p = 0.0502). Correlations between CT and MR for 
the remaining extracted features, EBF, EIF, FLCCF, and MNF were not significant. These 
relationships are detailed in Table 3. 
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A broader inspection of the data revealed a preponderance of null values – i.e. 
extracted features which resulted in a measure of “0” – (23%) for features extracted from 
MRI, while only 2 null values resulted for features extracted from CT (2%). The majority 
of null values which resulted on MRI were from the same five patients (21%). However, 
scan acquisition parameters for these five cases did not significantly differ from the mean. 
The preponderance of null values for features extracted from MRI likely indicates an 
experimental error in the extraction process. Thus, it is not possible to determine whether 
a given extracted feature which resulted in a null value is due to experimental error or if 
the feature was truly not detected.  
For two patients, AWE measured 0 on both CT and MR. It is unclear whether these 
results were truly perfectly correlated or due to experimental error. When just one of these 
patients was removed from the Pearson correlation calculation (n = 18), AWE failed to 
show significance (r = 0.3137, 95% CI = -0.7862 – 0.9367, p = 0.6073). 












Table 2. Patient demographics and clinical characteristics; median (range) or n (%), 
 All patient characteristics (n = 19) 
Age at operation 66.0 (44-82) 
Gender 
     Male 
     Female 
 
  9 (47.4%) 
10 (52.6%) 
Time from scan to operation (weeks)   8.0 (2.9-30.3) 
Largest cyst size (cm)   2.7 (1.1-5.0) 
Radiographic features 
    None 
    Mural nodule, solid component, or both 
 
13 (68.4%) 
  6 (31.6%) 
Grade of dysplasia 
    Low grade 
    Intermediate grade 
    High grade 
 
  6 (31.6%) 
  6 (31.6%) 




Table 3. Pearson correlation of radiomics features extracted from MR and CT in all 
patients (n=19). 
Feature r-value 95% CI p-value  
EBF  0.1262 -0.348 – 0.5489  0.6068 
EIF  0.0881 -0.3814 – 0.5214 0.7199 
FLCCF -0.01265 -0.4642 – 0.4441 0.9590 
AWE  0.4552  0.001236 – 0.7536 0.0502 





Comparison of MR and CT extracted radiomics features in patients stratified by 
risk and risk-associated features 
 Correlations between MR and CT radiomics features were performed separately for 
high-risk and low-risk patients. On initial analysis, a moderate correlation for AWE was 
observed in low-risk patients (n = 12, r = 0.6314, 95% CI = 0.09016 – 0.8847, p = 0.0277). 
When the previously identified patients for whom AWE measured 0 on both modalities 
were removed (n = 10), there remained a moderate correlation, but this was no longer 
significant (r = 0.4882, 95% CI = -0.2042 – 0.855, p = 0.1523). There were no correlations 
between MR and CT for the remaining investigated features.  
 Several radiomics features, including EBF, EIF and FLCCF, exhibited clear risk-
associated trends on CT. These trends are illustrated in Figure 6, such that high-risk 
patients consistently exhibited higher values than low-risk patients on EIF and FLCCF, and 
lower values on EBF. There were no risk-associated trends observed for any of the 
radiomics features extracted from MRI.    
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Figure 6: Correlations between radiomics features extracted from MRI and CT. 




 Further analysis was performed on a subset of patients who had a mural nodule, 
solid component, or both detected preoperatively (n = 6). Pearson correlations were 
calculated for each of the radiomics features extracted from MR and CT in this subset. 
Moderate but non-significant correlations were detected for FLCCF (r = 0.4736, 95% CI = 
-0.5489 – 0.9284, p = 0.3427), MNF (r = 0.4964, 95% CI = -0.5278 – 0.9323, p = 0.3166), 
EIF (r = 0.5523, 95% CI = -0.4699 – 0.9417, p = 0.2558) and AWE (r = 0.6628, 95% CI = 
-0.3220 – 0.9587, p = 0.1514). When one of the previously identified patients for whom 
AWE measured 0 on both modalities was removed from the calculation for AWE (n = 5), 
there was no longer a strong correlation between MR and CT for this feature (r = 0.3137, 
95% CI = -0.7862 – 0.9367, p = 0.6073). EBF did not show a correlation between MR and 
CT. However, the small sample size and presence of several null values limit the true 
significance of these correlations. These relationships are further detailed in Table 4.   
 
Table 4. Pearson correlation of radiomics features extracted from MR and CT in patients 
with preoperatively identified mural nodule, solid feature, or both (n=6).  
Feature r-value 95% CI p-value  
EBF 0.1332 -0.7606 – 0.8526 0.8014 
EIF 0.5523 -0.4699 – 0.9417 0.2558 
FLCCF 0.4736 -0.5489 – 0.9284 0.3427 
AWE 0.6628 -0.3220 – 0.9587 0.1514 




 To estimate risk prediction value of MRI and CT separately, scores for each of the 
following patient categories were averaged for comparison: high-risk, low-risk, presence 
of mural nodule, solid component or both, and absence of mural nodule or solid component. 
Grouped averaged values are illustrated in Figure 7.  
While MNF extracted from CT reliably and accurately predicts both high risk and 
the presence of mural nodule or solid component, MNF extracted from MRI did not. None 
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Figure 7. Performance of radiomics features by modality. Each data point represents 
averaged feature performance scores within a given subset of patients, stratified by 
modality. Top, radiomics feature detection of mural nodule or solid component on MRI, 
left, and CT, right. Bottom, radiomics feature detection of high-risk or low-risk IPMN on 





 The present study investigated whether a BD-IPMN malignancy risk prediction 
model which demonstrated strong potential on CT would show similar results on MRI. 
Since both imaging modalities could detect enhancement after intravenous injection of 
contrast, there was a potential for MRI to perform similarly to CT. Accurate preoperative 
risk stratification is crucial for determining appropriate clinical management in patients 
with BD-IPMN. This would better enable clinicians to direct patients with high risk of 
malignancy toward resection and advise patients with low risk or benign disease to avoid 
unnecessary surgery. Although management guidelines for BD-IPMN have improved 
within the last two decades, there is no reliable preoperative method for distinguis hing 
high- and low-risk BD-IPMN, and the majority of surgically eligible patients still undergo 
resection. 
 The current study employed five radiomics features which previously demonstrated 
better risk prediction for BD-IPMN than routine clinical and qualitative radiographic 
assessment. These novel features were extracted from CT images in two prior studies 
completed at MSKCC. Given the success of these predictive models on CT (Chakraborty 
et al. 2018; Attiyeh, Chakraborty, Gazit, et al. 2018), the present study aimed to investigate 
whether these features could also predict risk of malignancy on MRI.  
 Among the five radiomics features investigated, average-weighted eccentricity 
(AWE) was moderately correlated between the two imaging modalities. The relationship 
was moderate and approached significance when all patients (n = 19) were included in the 
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analysis (r = 0.4552, 95% CI = 0.001236 – 0.7536, p = 0.0502). When correlations of AWE 
on MRI and CT were investigated separately in low-risk, high-risk, and patients with a 
mural nodule or solid component, AWE showed a moderate, significant correlation in low-
risk patients (r = 0.6314, 95% CI = 0.09016 – 0.8847, p = 0.0277), a moderate but non-
significant correlation in patients with a mural nodule or solid component (r = 0.6628, 95% 
CI = -0.3220 – 0.9587, p = 0.1514), but no relationship in high-risk patients (r = -0.1956, 
95% CI = -0.8269 – 0.6538, p = 0.6743). However, closer inspection of the data revealed 
two low-risk patients for whom AWE measured 0 on both modalities. Further, one of these 
low-risk patients also had a preoperatively identified mural nodule. When these patients 
were removed from the analyses, no correlations were seen for AWE between MRI and 
CT. This suggests that data from these controversial patients may be unreliable, and that 
the skew toward increased correlation caused by inclusion of these data may have produced 
misleading results. Nevertheless, it is important to consider that selectively removing data 
points may introduce bias.  
 The present study shows that radiomics features designed to predict risk of BD-
IPMN malignancy on CT images are not translatable to MRI. This is most clearly exhibited 
by the higher amount of null values in MRI-extracted radiomics features (23%), with only 
two null values for CT-extracted features. The most likely cause of this experimental error 
is that the thresholding method employed for CT was not transferable to MR. Additiona lly , 
an adjusted prediction model in which the feature parameters are designed more 
specifically for MRI would likely exhibit greater success. In addition to investigating MRI 
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radiomics as a comparison to the reference standard of CT, further research should be 
dedicated to the investigation of MRI radiomics on its own for risk prediction in BD-IPMN.   
 This study had several limitations, including manual cyst and pancreas 
segmentation, which requires a radiologist’s subjective interpretation. The restriction of 
our cohort to resected patients is another limitation. As a result of recently updated 
guidelines for clinical management of IPMN, many patients who present with BD-IPMN 
that do not show high-risk or worrisome stigmata are no longer recommended for resection 
(Tanaka et al. 2017). Thus, a cohort which only includes patients who undergo resection 
does not accurately represent the general BD-IPMN patient population. Nevertheless, the 
clinical and demographic characteristics of included patients, detailed in Table 2, illustrate 
that our sample is a realistic approximation of the surgically resected BD-IPMN patient 
population. 
Additional limitations include a small sample size defined by our inclusion criteria, 
heterogeneous imaging protocols with a range of pixel resolution, and retrospective data 
collection. Variations in MRI protocol, including type of contrast agent, portal venous 
phase acquisition time, and acquisition parameters including repetition time, echo time, 
slice spacing and pixel resolution, may have had a confounding influence. However, 
Waugh et al. (2011) have demonstrated that variation in scan acquisition parameters have 
less of an influential effect on MRI radiomics analysis of foam phantoms completed at a 
magnetic field strength of 1.5T, compared to those completed at 3T, and the majority of 
MRIs (79%) in the present study were completed at a magnetic field strength of 1.5T 
(Waugh et al. 2011). Since this study was performed on foam phantoms rather than 
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patients, the effect of field strength on actual clinical patients remains unclear. 
Alternatively, while extraction of radiomics features from scans completed at a magnetic 
field strength of 1.5T may be more forgiving with regard to variability in acquisition 
parameters, radiomics analysis may also perform superiorly when scans are captured at a 
higher magnetic field strength, mainly because of the potential for a higher signal-to-noise 
ratio (Waugh et al. 2011; Mayerhoefer et al. 2009; Jirak, Dezortova, and Hajek 2004; Schad 
2004).  
Patients typically present to MSKCC for initial assessment following referral from 
primary care practices and acquisition of a baseline radiographic assessment at an external 
imaging facility. Thus, the application of a quantitative risk prediction model to 
heterogeneously captured scans from a range of external institutions realistically 
approximates the initial qualitative assessment of patients at MSKCC. Although there has 
been an effort among radiologists to standardize imaging protocols, it may be more feasible 
to develop more adaptable novel quantitative methods for widespread application than to 
adjust longstanding procedures amongst a multitude of imaging centers to a single 
standard. Additionally, radiomics studies have been criticized for poor reproducibility and 
inconsistent reporting due to a lack of reporting guidelines for radiomics results (Traverso 
et al. 2018; Gillies, Kinahan, and Hricak 2016). Thus, there is a strong need for 
accommodation of some flexibility in imaging protocols for multi-institutional validation 
of radiomics feature analysis. 
 There is also a need for prospective trials to validate the use of radiomics analysis 
in the clinical setting. To date, most radiomics research has been conducted in the 
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retrospective setting, in surgically resected patients with IPMN, but prospective data is 
needed to validate the real-time use of radiomics features for prediction of malignancy and 
to determine the value of radiomics for enhanced clinical decision making. Further, 
prospective trials would enable imaging protocol consistency, providing for stronger 
control in study design.  
A strength of the present study is the application of 3D whole-lesion radiomics 
analysis. 2D image analysis was performed on all image slices and the extracted features 
were averaged over a volume of interest, enabling 3D radiomics analysis of the entire cystic 
lesion. Such 3D radiomics takes additional texture information into account by 
incorporating volumetric texture data across slices. Several studies have demonstrated that 
a volumetric analysis approach is advantageous for evaluation of breast and brain lesions 
on MRI (Chen et al. 2007; Mahmoud-Ghoneim et al. 2003; Shen et al. 2017).  
 Future studies should also investigate the use of radiogenomics to predict risk of 
malignancy in BD-IPMN. Radiogenomics is the association of radiomic imaging features 
with gene and molecular expression patterns and has shown great promise in recent years. 
While genomic profiling is performed on a small sample of the tumor, radiogenomics can 
yield genomic information from the entire tumor, thus accounting for tumor heterogeneity 
and avoiding the pitfalls of sampling error. Thus, radiogenomics can be used for cross-
validation of genomic profiling and has the potential to provide additional pertinent 
information which could indicate further testing, inform prognosis and aid clinical decision 
making (Gillies, Kinahan, and Hricak 2016). Future studies might investigate the 
association of radiomic imaging features with molecular profiles of IPMN cystic fluid.   
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 The present study is among the first to compare the use of radiomics analysis in 
two imaging modalities used in assessing risk of malignancy in patients with BD-IPMN. 
Although the results of the present study alone do not show a successful translation of CT 
radiomics prediction models to MRI-based radiomics in IPMN risk prediction, these 
findings had several important limitations, noted above. Indeed, the previously 
summarized findings of Hoffman et al. (2017) suggest that more research on the use of 
MRI-derived radiomics in IPMN risk assessment is warranted (Hoffman et al. 2017). While 
the present study and its predecessors lay the foundation for the application of radiomics 
in IPMN assessment, larger external validation cohorts and prospective analysis are needed 
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